After the approval of immune checkpoint inhibitors, overall survival among US patients with advanced-stage cancer improved, but disparities between uninsured and privately insured widened.

Median progression-free survival was 3.7 months, with 44.4% of patients being progression free at 6 months and 32.3% at 12 ...

Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its ...

Panelists discuss treatment considerations for metastatic melanoma with high tumor burden, highlighting the preference for immune checkpoint combinations like nivolumab with relatlimab for durable ...

A new pilot clinical study will explore the safety and effectiveness of 2 anti-canine monoclonal antibodies on solid tumors ...

DelveInsight’s, “Metastatic Urothelial Carcinoma Pipeline Insight, 2025” report provides comprehensive insights about 40+ ...